Bactolife Raises €30 Million Series B to Commercialize Gut Health Binding Proteins Technology
核心洞察
Bactolife (搜索) secured over €30 million in Series B funding led by Cross Border Impact Ventures (搜索) and EIFO (搜索) to advance its novel Binding Proteins (搜索) technology for gut health applications.
The Danish biotech company plans to launch its first Binding Protein products under the Helm brand in the United States in 2026, targeting both human and animal health markets.
The funding will support clinical validation studies across multiple regions and scale manufacturing operations to meet global demand for the food-grade gut health solutions.
Danish biotech company Bactolife (搜索) has successfully closed a €30 million Series B financing round to advance the commercialization of its innovative Binding Proteins (搜索) technology, a novel approach to gut health management that targets harmful toxins while preserving beneficial microbiota. The funding round was led by Cross Border Impact Ventures (搜索) (CBIV) and the Export and Investment Fund of Denmark (EIFO (搜索)), with continued participation from existing investors Novo Holdings (搜索) and ATHOS (搜索).
The Series B investment represents a significant milestone for Bactolife (搜索), which has been developing its precision biotechnology platform since receiving seed financing from Novo Holdings (搜索) in 2021. The company previously completed a Series A round in 2023, also backed by Novo Holdings, demonstrating sustained investor confidence in its gut health solutions.
Revolutionary Binding Proteins Technology
Bactolife (搜索)'s core innovation centers on Binding Proteins (搜索), small antibody fragments specifically engineered to neutralize unwanted elements in the gastrointestinal system without disrupting the natural microbiota balance. These proteins are discovered from natural camelid immunoglobulins and manufactured through precision fermentation processes, enabling stable and affordable large-scale production.
The technology represents a transformative approach to proactive healthcare, offering a food-grade solution that can be seamlessly integrated into everyday nutrition through dietary supplements, functional foods and beverages, and feed additives for animal health applications.
Sebastian Søderberg, CEO of Bactolife (搜索), emphasized the significance of the funding milestone: "Today's successful close of our Series B round sets the stage for exciting years ahead as we prepare to launch our innovative products in 2026. This funding will enable us to clinically validate, scale, and commercialise our Binding Proteins (搜索), taking Bactolife's solutions to a broad audience."
Strategic Market Entry and Global Expansion
The Series B proceeds will fund several critical growth initiatives, including the execution of comprehensive human study programs across the United States, European Union, Asia, and low- and middle-income countries (LMICs). Bactolife (搜索) plans to launch its first commercial products under the ingredient brand "Helm" for human health applications in the United States in 2026, followed by expansion into Asian and European markets.
The company has committed to ensuring accessibility of its technology for women and children in low- and middle-income countries, addressing global gut health challenges with particular focus on vulnerable populations.
Donna Parr, Managing Partner at Cross Border Impact Ventures (搜索), highlighted the dual impact potential: "Bactolife (搜索)'s Binding Proteins (搜索) have the potential to strengthen gut resilience for mothers and children in low- and middle-income countries by providing a scalable, food-grade solution that can be integrated into everyday nutrition. At the same time, we are excited about the significant growth opportunity across North America, Europe, and Asia where the market opportunity is massive."
Manufacturing Scale-Up and Clinical Validation
The funding will enable Bactolife (搜索) to scale its manufacturing and supply operations to meet anticipated global demand while maintaining the advanced biomanufacturing processes that ensure product quality and affordability. The company's precision fermentation approach allows for consistent production of Binding Proteins (搜索) that can be incorporated into regular diets and feeds.
Clinical validation remains a key priority, with the Series B funding supporting comprehensive human studies designed to demonstrate the efficacy and safety of Binding Proteins (搜索) across diverse populations and applications.
Investor Confidence and Planetary Health Impact
Sophia Heyde, Vice President of Planetary Health Investments at Novo Holdings (搜索), expressed satisfaction with the company's progress: "As the first institutional investor in Bactolife (搜索), we are very pleased to welcome Cross-Border Impact Ventures and EIFO (搜索) to the investment syndicate and the board. Bactolife has consistently demonstrated a strong commitment to advancing its novel precision biotechnology platform for establishing a healthy gut flora."
The investment aligns with Novo Holdings (搜索)' Planetary Health ambitions, supporting technologies that deliver meaningful benefits for both human and animal health while addressing antimicrobial resistance (搜索) challenges.
Bactolife (搜索)'s approach positions the company in the rapidly growing nutraceuticals market, meeting demand for scientifically proven specialty ingredients that offer evidence-based health benefits. The technology's versatility across multiple product formats ensures broad application relevance in both human and veterinary medicine.